CDK9 and acute myeloid leukemia: MLL1-rearranged malignancies exhibit specific CDK9-dependent gene expression features typical of hematopoietic progenitor cells.376–378 Accordingly, pharmacological inhibition of CDK9 reduces disease progression and improves survival in mouse models of MLL-driven and AML malignancies.177